These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


333 related items for PubMed ID: 35603651

  • 1. [Ponatinib inhibits the proliferation of SNU-449 human hepatocellular cancer cells and blocks MAPK and PDK1/AKT/mTOR signaling pathways].
    Liu C, Pei J, Mu X, Yu B, Gong T, Liang W.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 May; 38(5):425-431. PubMed ID: 35603651
    [Abstract] [Full Text] [Related]

  • 2. Ponatinib Inhibits Proliferation and Induces Apoptosis of Liver Cancer Cells, but Its Efficacy Is Compromised by Its Activation on PDK1/Akt/mTOR Signaling.
    Liu C, Mu X, Wang X, Zhang C, Zhang L, Yu B, Sun G.
    Molecules; 2019 Apr 07; 24(7):. PubMed ID: 30959969
    [Abstract] [Full Text] [Related]

  • 3. Dasatinib inhibits proliferation of liver cancer cells, but activation of Akt/mTOR compromises dasatinib as a cancer drug.
    Liu C, Zhu X, Jia Y, Chi F, Qin K, Pei J, Zhang C, Mu X, Zhang H, Dong X, Xu J, Yu B.
    Acta Biochim Biophys Sin (Shanghai); 2021 Jul 05; 53(7):823-836. PubMed ID: 33961012
    [Abstract] [Full Text] [Related]

  • 4. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, Evers BM.
    Anticancer Res; 2010 Dec 05; 30(12):4951-8. PubMed ID: 21187475
    [Abstract] [Full Text] [Related]

  • 5. PI3K/mTOR dual-inhibition with VS-5584 enhances anti-leukemic efficacy of ponatinib in blasts and Ph-negative LSCs of chronic myeloid leukemia.
    Kayabasi C, Yelken BO, Asik A, Okcanoglu TB, Sogutlu F, Gasimli R, Susluer SY, Saydam G, Avci CB, Gunduz C.
    Eur J Pharmacol; 2021 Nov 05; 910():174446. PubMed ID: 34461124
    [Abstract] [Full Text] [Related]

  • 6. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
    Liu Y, Chen X, Luo Z.
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun 05; 30(6):592-6. PubMed ID: 24909280
    [Abstract] [Full Text] [Related]

  • 7. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA, Chang HL, Ong JR, Lee WH, Yeh CT, Tsai JT.
    Cells; 2020 Mar 18; 9(3):. PubMed ID: 32197467
    [Abstract] [Full Text] [Related]

  • 8. MicroRNA-29b Inhibits Angiogenesis by Targeting VEGFA through the MAPK/ERK and PI3K/Akt Signaling Pathways in Endometrial Carcinoma.
    Chen HX, Xu XX, Tan BZ, Zhang Z, Zhou XD.
    Cell Physiol Biochem; 2017 Mar 18; 41(3):933-946. PubMed ID: 28222438
    [Abstract] [Full Text] [Related]

  • 9. Ropivacaine suppresses tumor biological characteristics of human hepatocellular carcinoma via inhibiting IGF-1R/PI3K/AKT/mTOR signaling axis.
    Zhang R, Lian Y, Xie K, Cai Y, Pan Y, Zhu Y.
    Bioengineered; 2021 Dec 18; 12(2):9162-9173. PubMed ID: 34696683
    [Abstract] [Full Text] [Related]

  • 10. SODD Promotes Lung Cancer Tumorigenesis by Activating the PDK1/AKT and RAF/MEK/ERK Signaling.
    Bao F, An S, Yang Y, Xu TR.
    Genes (Basel); 2023 Mar 30; 14(4):. PubMed ID: 37107587
    [Abstract] [Full Text] [Related]

  • 11. PDK1 is a potential therapeutic target against angiosarcoma cells.
    Wada M, Horinaka M, Yasuda S, Masuzawa M, Sakai T, Katoh N.
    J Dermatol Sci; 2015 Apr 30; 78(1):44-50. PubMed ID: 25726712
    [Abstract] [Full Text] [Related]

  • 12. [Estradiol activates MAPK signaling pathway by estrogen induced VEGF and bFGF in endometrial cancer cells].
    Lu Y, Jiang S, Zhang J, Song H, Li L.
    Zhonghua Fu Chan Ke Za Zhi; 2014 Dec 30; 49(12):925-31. PubMed ID: 25608994
    [Abstract] [Full Text] [Related]

  • 13. A Ferulic Acid Derivative FXS-3 Inhibits Proliferation and Metastasis of Human Lung Cancer A549 Cells via Positive JNK Signaling Pathway and Negative ERK/p38, AKT/mTOR and MEK/ERK Signaling Pathways.
    Yue SJ, Zhang PX, Zhu Y, Li NG, Chen YY, Li JJ, Zhang S, Jin RY, Yan H, Shi XQ, Tang YP, Duan JA.
    Molecules; 2019 Jun 08; 24(11):. PubMed ID: 31181779
    [Abstract] [Full Text] [Related]

  • 14. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
    Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Evers BM.
    J Surg Res; 2012 Aug 08; 176(2):542-8. PubMed ID: 22261591
    [Abstract] [Full Text] [Related]

  • 15. Local anesthetic bupivacaine inhibits proliferation and metastasis of hepatocellular carcinoma cells via suppressing PI3K/Akt and MAPK signaling.
    Wang L, Guo W, Guan H, Yan N, Cai X, Zhu L.
    J Biochem Mol Toxicol; 2021 Oct 08; 35(10):e22871. PubMed ID: 34338398
    [Abstract] [Full Text] [Related]

  • 16. Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.
    Niu NK, Wang ZL, Pan ST, Ding HQ, Au GH, He ZX, Zhou ZW, Xiao G, Yang YX, Zhang X, Yang T, Chen XW, Qiu JX, Zhou SF.
    Drug Des Devel Ther; 2015 Oct 08; 9():1555-84. PubMed ID: 25792811
    [Abstract] [Full Text] [Related]

  • 17. Single Agent and Synergistic Activity of the "First-in-Class" Dual PI3K/BRD4 Inhibitor SF1126 with Sorafenib in Hepatocellular Carcinoma.
    Singh AR, Joshi S, Burgoyne AM, Sicklick JK, Ikeda S, Kono Y, Garlich JR, Morales GA, Durden DL.
    Mol Cancer Ther; 2016 Nov 08; 15(11):2553-2562. PubMed ID: 27496136
    [Abstract] [Full Text] [Related]

  • 18. Effects of orexin A on glucose metabolism in human hepatocellular carcinoma in vitro via PI3K/Akt/mTOR-dependent and -independent mechanism.
    Liu Y, Zhao Y, Guo L.
    Mol Cell Endocrinol; 2016 Jan 15; 420():208-16. PubMed ID: 26549689
    [Abstract] [Full Text] [Related]

  • 19. NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma.
    Dimri M, Humphries A, Laknaur A, Elattar S, Lee TJ, Sharma A, Kolhe R, Satyanarayana A.
    Hepatology; 2020 Feb 15; 71(2):549-568. PubMed ID: 31215069
    [Abstract] [Full Text] [Related]

  • 20. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
    Tsurutani J, West KA, Sayyah J, Gills JJ, Dennis PA.
    Cancer Res; 2005 Sep 15; 65(18):8423-32. PubMed ID: 16166321
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 17.